Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Laboratorios Farmaceuticos RoviLABFF 99 Cyclically Adjusted Price-to-FCF is 37.32 as of Aug. 19, 2026, which is 65% below its 10-year median of 107.72. GuruFocus rates LABFF with a GF Score™ of 99/100 and a GF Value™ of $85.94 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 329 Drug Manufacturers companies, Laboratorios Farmaceuticos Rovi ranks worse than 71.12% on this metric.
The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Price-to-FCF or its related term are showing as below:
LABFF'
s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 47.09 Med: 107.72 Max: 2670
Current: 50.25
During the past years, Laboratorios Farmaceuticos Rovi's highest Cyclically Adjusted Price-to-FCF was 2670.00. The lowest was 47.09. And the median was 107.72.
LABFF's Cyclically Adjusted Price-to-FCF is ranked worse than 71.12% of 329
companies
in the Drug Manufacturers industry
Industry Median: 27.64
vs LABFF: 50.25
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
Laboratorios Farmaceuticos Rovi's adjusted free cash flow per share data for the three months ended in Jun. 2026 was $1.319. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $1.80 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.
Laboratorios Farmaceuticos Rovi Cyclically Adjusted Price-to-FCF Related Terms
Laboratorios Farmaceuticos Rovi Cyclically Adjusted Price-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LABFF vs ZTS, UTHR, VTRS: Cyclically Adjusted Price-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Price-to-FCF falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted Price-to-FCF of 37.32 mean?
Laboratorios Farmaceuticos Rovi (LABFF) has a Cyclically Adjusted Price-to-FCF of 37.32 as of Aug. 19, 2026. Cyclically Adjusted Price-to-FCF Ratio is the ratio of share price to a company's inflation-adjusted FCF per share over a 10-year period. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is 65% below median its historical median of 107.72. Over the past decade, Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Price-to-FCF has ranged from 47.09 to 2,670.00. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #234 out of 329 companies in the Drug Manufacturers industry, placing it in the top 71.1%.
Is Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Price-to-FCF too high?
Laboratorios Farmaceuticos Rovi's current Cyclically Adjusted Price-to-FCF of 37.32 is 65% below median its 10-year median of 107.72. Over the past 10 years, this metric has ranged from a low of 47.09 to a high of 2,670.00. The Drug Manufacturers industry median Cyclically Adjusted Price-to-FCF is 27.64. Laboratorios Farmaceuticos Rovi's value of 37.32 is 35% above this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #234 out of 329 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Price-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #234 out of 329 companies for Cyclically Adjusted Price-to-FCF. This places Laboratorios Farmaceuticos Rovi in the lower half of its industry. The industry median Cyclically Adjusted Price-to-FCF is 27.64. Laboratorios Farmaceuticos Rovi's value of 37.32 is 35% above this benchmark. Historically, Laboratorios Farmaceuticos Rovi's own Cyclically Adjusted Price-to-FCF has ranged from 47.09 to 2,670.00 over the past decade. While the company's 10-year median is 107.72 vs. the industry median of 27.64, Laboratorios Farmaceuticos Rovi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Price-to-FCF for a Drug Manufacturers company?
The median Cyclically Adjusted Price-to-FCF among Drug Manufacturers companies is 27.64, based on 329 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted Price-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted Price-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current Cyclically Adjusted Price-to-FCF of 37.32 is 35% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Price-to-FCF mean?
A high Cyclically Adjusted Price-to-FCF can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted Price-to-FCF Ratio is the ratio of share price to a company's inflation-adjusted FCF per share over a 10-year period. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median Cyclically Adjusted Price-to-FCF is 27.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current Cyclically Adjusted Price-to-FCF is 37.32, which is 65% below median its own 10-year median of 107.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (LABFF) is currently considered Modestly Undervalued. The stock's GF Value™ is $85.94, compared to a current price of $67.17 — trading 21.8% below its estimated fair value. The current Cyclically Adjusted Price-to-FCF is 37.32, which is 65% below median its 10-year median of 107.72 and 35% above the Drug Manufacturers industry median of 27.64. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 99/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Price-to-FCF calculated?
Cyclically Adjusted Price-to-FCF is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current Cyclically Adjusted Price-to-FCF is 37.32 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be undervalued.
The current stock price of $67.17 is trading 21.8% below its estimated GF Value™ of $85.94.
GuruFocus considers Laboratorios Farmaceuticos Rovi to be Modestly Undervalued.
Key valuation signals for LABFF:
Cyclically Adjusted Price-to-FCF: 37.32 (65% below median its 10-year median of 107.72)
GF Value™: $85.94 vs. price of $67.17 (21.8% below fair value)
Industry Position: 35% above the Drug Manufacturers median (#234 of 329)
No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
99GF Score
Get the complete analysis for LABFF
Cyclically Adjusted Price-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABFF has been successfully added to your 
